New Nasal Spray Reverses Brain Aging and Inflammation

Scientists reverse brain aging with a nasal spray April 14, 2026 – A new nasal spray developed by researchers at Texas A&M University has shown the ability to reverse key signs of brain aging in preclinical models, offering a potential breakthrough in the fight against cognitive decline and neurodegenerative diseases. The therapy, described in a study supported by the National Institute on Aging, uses intranasal delivery of extracellular vesicles—microscopic biological parcels that carry therapeutic molecules directly to the brain. In aging models, just two doses of the spray led to significant reductions in chronic brain inflammation, restored mitochondrial function, and improved memory and cognitive flexibility. Researchers refer to the age-related inflammatory process as “neuroinflammaging,” a persistent, low-grade inflammation in the brain that contributes to brain fog, memory loss, and increased risk of conditions like Alzheimer’s disease. The nasal spray targets this process by calming inflammatory activity in the hippocampus, a brain region critical for learning, and memory. According to the study, cognitive improvements were observed within weeks of treatment and lasted for months after the final dose. The therapy was equally effective in both male and female models, suggesting broad potential applicability. Treated subjects showed restored ability to recognize familiar objects and adapt to environmental changes—key indicators of healthy brain function. Beyond aging, the research team believes the approach could be adapted to support recovery after stroke or sluggish the progression of Alzheimer’s disease. Texas A&M has filed a U.S. Patent for the technology, marking a step toward future clinical development. Dr. Ashok Shetty, university distinguished professor and associate director of the Institute for Regenerative Medicine at Texas A&M, led the study alongside senior research scientists Dr. Madhu Leelavathi Narayana and Dr. Maheedhar Kodali. The team emphasized the importance of their collaboration with the National Institute on Aging in advancing the work. Although the results are promising, the therapy remains in the preclinical stage. Further studies will be needed to determine its safety and effectiveness in humans before it can be considered for clinical use. Key Takeaways – A nasal spray using extracellular vesicles reduced brain inflammation and improved memory in aging models – Two doses produced rapid and lasting cognitive improvements, with effects persisting for months – The therapy restored mitochondrial function and reduced neuroinflammaging in the hippocampus – Benefits were observed in both male and female models, indicating broad potential efficacy – Researchers suggest future applications in stroke recovery and Alzheimer’s disease prevention – A patent has been filed, but human trials are still required before clinical availability Frequently Asked Questions How does the nasal spray work? The spray delivers extracellular vesicles through the nasal passage, allowing them to reach the brain directly and target inflammation and cellular energy deficits linked to brain aging. What is neuroinflammaging? Neuroinflammaging refers to chronic, low-grade inflammation in the brain that accumulates with age and contributes to cognitive decline and neurodegenerative disease risk. Has this been tested in humans? No. The current findings are based on preclinical models. Human clinical trials have not yet been conducted. How long do the effects last? In the study, cognitive improvements lasted for months after just two doses, indicating a durable response. Could this prevent Alzheimer’s disease? While not proven to prevent Alzheimer’s, the therapy targets underlying mechanisms—such as inflammation and mitochondrial dysfunction—that are involved in the disease’s progression. Researchers suggest it may one day be adapted for such applications. Is the nasal spray available now? No. The technology is patent-pending and still requires further testing before it could be approved for human use.